Supplemental Figure 4 from Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts

Supplemental Figure 4: Evolution of body weight during treatment, presented as relative body weight (% change from normalized baseline) ± standard deviation. Figure 2F depicts the first phase of the experiment of STS336SynSa, while Figure 2G depicts the complete experiment. Mice sacrificed prior to end of experiment are removed from data after date of scarification. 3x/4x: 3 or 4 mice of the same group were sacrificed on the same day; * p<0.05; CRS: CIC-rearranged sarcoma; DDLPS: dedifferentiated liposarcoma; LMS: leiomyosarcoma; ns: not significant; STS: soft tissue sarcoma; TV: tumor volume; SynSa: synovial sarcoma.